Fig. 3

DOX uptake in peripheral blood lymphocytes subpopulations collected from BC patients immediately after the first cycle of NAC. A CD8⁺ and CD4⁺ distribution in BC patients’ PBMC collected immediately after the first cycle of NAC. B CD8⁺ and CD4⁺ distribution in DOX⁺ population of BC patients’ PBMC collected immediately after the first cycle of NAC. C Mean DOX fluorescence intensity in DOX⁺ T cells populations from BC patients’ PBMC collected immediately after the first cycle of NAC. Statistical significance: *p < 0.05 (One-way ANOVA). D Representative dot-plot of distribution of CD4⁺ T cells subpopulations from BC patients’ PBMC collected immediately after the first cycle of NAC. E CD4⁺ T cells distribution in BC patients’ PBMC collected immediately after the first cycle of NAC. F Mean DOX fluorescence intensity in DOX⁺/CD4⁺ T cells subpopulations from BC patients’ PBMC collected immediately after the first cycle of NAC. Statistical significance: **p < 0.01, ***p < 0.005 (One-way ANOVA) (G) Representative dot-plot of distribution of CD8⁺ T cells subpopulations from BC patients’ PBMC collected immediately after the first cycle of NAC. H CD8⁺ T cells distribution in BC patients’ PBMC collected immediately after the first cycle of NAC. I Mean DOX fluorescence intensity in DOX⁺/CD8⁺ T-cells subpopulations from BC patients’ PBMC collected immediately after the first cycle of NAC. Statistical significance: ***p < 0.005, ****p < 0.001 (One-way ANOVA). All assessments have been performed at least on PBMCs collected from at least 3 patients